107 related articles for article (PubMed ID: 14527551)
1. One-electron reduction characteristics of N(3)-substituted 5-fluorodeoxyuridines synthesized as radiation-activated prodrugs.
Tanabe K; Mimasu Y; Eto A; Tachi Y; Sakakibara S; Mori M; Hatta H; Nishimoto S
Bioorg Med Chem; 2003 Oct; 11(21):4551-6. PubMed ID: 14527551
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and one-electron reduction characteristics of radiation-activated prodrugs possessing two 5-fluorodeoxyuridine units.
Tanabe K; Sugiura M; Ito T; Nishimoto S
Bioorg Med Chem; 2012 Sep; 20(17):5164-8. PubMed ID: 22847019
[TBL] [Abstract][Full Text] [Related]
3. Hypoxia-selective activation of 5-fluorodeoxyuridine prodrug possessing indolequinone structure: radiolytic reduction and cytotoxicity characteristics.
Tanabe K; Makimura Y; Tachi Y; Imagawa-Sato A; Nishimoto S
Bioorg Med Chem Lett; 2005 May; 15(9):2321-4. PubMed ID: 15837317
[TBL] [Abstract][Full Text] [Related]
4. In vitro and in vivo evaluation of novel antitumor prodrugs of 5-fluoro-2'-deoxyuridine activated by hypoxic irradiation.
Shibamoto Y; Tachi Y; Tanabe K; Hatta H; Nishimoto S
Int J Radiat Oncol Biol Phys; 2004 Feb; 58(2):397-402. PubMed ID: 14751508
[TBL] [Abstract][Full Text] [Related]
5. Reductive activation of 5-fluorodeoxyuridine prodrug possessing azide methyl group by hypoxic X-irradiation.
Tanabe K; Ishizaki J; Ando Y; Ito T; Nishimoto S
Bioorg Med Chem Lett; 2012 Feb; 22(4):1682-5. PubMed ID: 22248856
[TBL] [Abstract][Full Text] [Related]
6. Enzymatic activation of indolequinone-substituted 5-fluorodeoxyuridine prodrugs in hypoxic cells.
Jiho Y; Kurihara R; Kawai K; Yamada H; Uto Y; Tanabe K
Bioorg Med Chem Lett; 2019 Jun; 29(11):1304-1307. PubMed ID: 30975626
[TBL] [Abstract][Full Text] [Related]
7. A photoactivated prodrug.
Wei Y; Yan Y; Pei D; Gong B
Bioorg Med Chem Lett; 1998 Sep; 8(18):2419-22. PubMed ID: 9873553
[TBL] [Abstract][Full Text] [Related]
8. A new class of 5-fluoro-2'-deoxyuridine prodrugs conjugated with a tumor-homing cyclic peptide CNGRC by ester linkers: synthesis, reactivity, and tumor-cell-selective cytotoxicity.
Zhang Z; Hatta H; Tanabe K; Nishimoto S
Pharm Res; 2005 Mar; 22(3):381-9. PubMed ID: 15835743
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and biological evaluation of butanoate, retinoate, and bis(2,2,2-trichloroethyl)phosphate derivatives of 5-fluoro-2'-deoxyuridine and 2',5-difluoro-2'-deoxyuridine as potential dual action anticancer prodrugs.
Xia Z; Wiebe LI; Miller GG; Knaus EE
Arch Pharm (Weinheim); 1999 Aug; 332(8):286-94. PubMed ID: 10489539
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and biological activity of novel 5-fluoro-2'-deoxyuridine phosphoramidate prodrugs.
Freel Meyers CL; Hong L; Joswig C; Borch RF
J Med Chem; 2000 Nov; 43(22):4313-8. PubMed ID: 11063625
[TBL] [Abstract][Full Text] [Related]
11. Floxuridine Oligomers Activated under Hypoxic Environment.
Morihiro K; Ishinabe T; Takatsu M; Osumi H; Osawa T; Okamoto A
J Am Chem Soc; 2021 Mar; 143(9):3340-3347. PubMed ID: 33648338
[TBL] [Abstract][Full Text] [Related]
12. Comparison of 5-fluorouracil and 5-fluoro-2'-deoxyuridine as an effector in radiation-activated prodrugs.
Shibamoto Y; Mimasu Y; Tachi Y; Hatta H; Nishimoto S
J Chemother; 2002 Aug; 14(4):390-6. PubMed ID: 12420858
[TBL] [Abstract][Full Text] [Related]
13. Induction of cell cycle-dependent cytotoxicity and apoptosis by new heterodinucleoside phosphate dimers of 5-fluorodeoxyuridine in PC-3 human prostate cancer cells.
Cattaneo-Pangrazzi RM; Schott H; Wunderli-Allenspach H; Derighetti M; Schwendener RA
Biochem Pharmacol; 2000 Dec; 60(12):1887-96. PubMed ID: 11108805
[TBL] [Abstract][Full Text] [Related]
14. The achievement of mass balance by simultaneous quantification of floxuridine prodrug, floxuridine, 5-fluorouracil, 5-dihydrouracil, α-fluoro-β-ureidopropionate, α-fluoro-β-alanine using LC-MS.
Tsume Y; Provoda CJ; Amidon GL
J Chromatogr B Analyt Technol Biomed Life Sci; 2011 Apr; 879(13-14):915-20. PubMed ID: 21450537
[TBL] [Abstract][Full Text] [Related]
15. Radiolytic activation of a cytarabine prodrug possessing a 2-oxoalkyl group: one-electron reduction and cytotoxicity characteristics.
Hirata N; Fujisawa Y; Tanabe K; Harada H; Hiraoka M; Nishimoto S
Org Biomol Chem; 2009 Feb; 7(4):651-4. PubMed ID: 19194578
[TBL] [Abstract][Full Text] [Related]
16. Synthesis of the cyclic and acyclic acetal derivatives of 1-(3-C-ethynyl-beta-D-ribo-pentofuranosyl)cytosine, a potent antitumor nucleoside. Design of prodrugs to be selectively activated in tumor tissues via the bio-reduction-hydrolysis mechanism.
Nomura M; Shuto S; Matsuda A
Bioorg Med Chem; 2003 May; 11(11):2453-61. PubMed ID: 12735992
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and anticancer activities of amphiphilic 5-fluoro-2'-deoxyuridylic acid prodrugs.
Ludwig PS; Schwendener RA; Schott H
Eur J Med Chem; 2005 May; 40(5):494-504. PubMed ID: 15893023
[TBL] [Abstract][Full Text] [Related]
18. 5-FdUrd-araC heterodinucleoside re-establishes sensitivity in 5-FdUrd- and AraC-resistant MCF-7 breast cancer cells overexpressing ErbB2.
Strasser S; Maier S; Leisser C; Saiko P; Madlener S; Bader Y; Bernhaus A; Gueorguieva M; Richter S; Mader RM; Wesierska-Gadek J; Schott H; Szekeres T; Fritzer-Szekeres M; Krupitza G
Differentiation; 2006 Dec; 74(9-10):488-98. PubMed ID: 17177846
[TBL] [Abstract][Full Text] [Related]
19. Structure-activity relationship in Ftorafur (Tegafur) and related 5-FU prodrugs.
Zhuk R
Adv Exp Med Biol; 1998; 431():677-80. PubMed ID: 9598151
[No Abstract] [Full Text] [Related]
20. Selective anticancer effects of 3',5'-dioctanoyl-5-fluoro-2'-deoxyuridine, a lipophilic prodrug of 5-fluoro-2'-deoxyuridine, dissolved in an oily lymphographic agent on hepatic cancer of rabbits bearing VX-2 tumor.
Fukushima S; Kawaguchi T; Nishida M; Juni K; Yamashita Y; Takahashi M; Nakano M
Cancer Res; 1987 Apr; 47(7):1930-4. PubMed ID: 3028618
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
